Xuzhou Central Hospital

Xuzhou, Jiangsu 221009

1 studies enrolling now · 13 studies all time

What they study most

Acute Non-cardioembolic Ischemic Stroke, Asthma, Breast Cancer, Cervical Cancer, Colorectal Neoplasms, Endometrial Carcinoma, Epithelial Ovarian Cancer, Extensive-Stage Small-Cell Lung Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, HER2-positive Breast Cancer, Head and Neck Squamous Cell Carcinoma

Studies at this site

• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer — Recruiting now
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma — Recruiting now
• A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — Running, not enrolling
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma — Completed
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) — Running, not enrolling
• Pulsed-Field Ablation With/Without Electrogram Mapping — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer — Running, not enrolling
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Running, not enrolling
• A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke — Completed
• Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC — Running, not enrolling
• A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC — Status unconfirmed